Additionally, FTO inhibitors such as CS1 (Bisantrene) and CS2 (Brequinar) have been shown to decrease the self-renewal capacity of leukemia stem/initiating cells (LSCs/LICs), highlighting their potential use as monotherapies or in combination with hypomethylating agents for treating refractory and relapsed cancers.227. The gene discussed is FTO; the disease is cancer.